Leading Pharmaceutical Biotechnology (00399) intends to grant a discount of approximately 20% on the total of 90 million shares of subscribed shares.

Zhixun, a financial news app, reported that Navigen Pharmaceuticals and Biotechnology (00399) announced that on July 15, 2025, the company entered into a subscription agreement with subscriber A, Zhang Biaobing. Subscriber A conditionally agreed to subscribe for, while the company conditionally agreed to issue and issue a total of 60 million shares. The subscription price for each subscribed share is 0.312 Hong Kong dollars. The subscribed shares will be issued and issued in accordance with the general authorization.